SCHEMBL6498593

SCHEMBL6498593

Cc1ccc(C(=O)N[C@H]2CN3CCC2CC3C)o1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.49
HPGD P15428 1/20 0.49
CHRNA7 P36544 7/20 0.48
CHRNB2 P17787 3/20 0.48
CHRNA4 P43681 3/20 0.48
KLK7 P49862 1/20 0.43
ALDH1A1 P00352 3/20 0.41
KMT2A Q03164 2/20 0.41
HSD17B10 Q99714 1/20 0.41
POLB P06746 2/20 0.41
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
PKM P14618 1/20 0.40
RAB9A P51151 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
CHRNB4 P30926 2/20 0.39
CHRNA3 P32297 2/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6496731 0.87 CHRNA7 (0.42) CHRNA7CHRNB2CHRNA4ALDH1A1POLB
SCHEMBL6489819 0.87 MEN1 (0.49) SMN1; SMN2HPGDCHRNA7CHRNB2CHRNA4
SCHEMBL6500481 0.85 ALDH1A1 (0.53) SMN1; SMN2HPGDCHRNA7CHRNB2CHRNA4
SCHEMBL6497753 0.83 ALDH1A1 (0.52) CHRNA7CHRNB2CHRNA4ALDH1A1KMT2A
SCHEMBL6488495 0.83 ALDH1A1 (0.46) HPGDCHRNA7CHRNB2CHRNA4ALDH1A1
SCHEMBL6495229 0.82 ALDH1A1 (0.53) SMN1; SMN2HPGDCHRNA7CHRNB2CHRNA4
SCHEMBL6500448 0.82 ALDH1A1 (0.52) SMN1; SMN2HPGDCHRNA7CHRNB2CHRNA4
SCHEMBL6489020 0.82 ALDH1A1 (0.52) SMN1; SMN2HPGDCHRNA7CHRNB2CHRNA4
SCHEMBL6499492 0.82 NPC1 (0.54) SMN1; SMN2HPGDALDH1A1KMT2APOLB
SCHEMBL6490046 0.81 ALDH1A1 (0.46) SMN1; SMN2CHRNA7CHRNB2CHRNA4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
EP-1442041-A1 AZABICYCLIC-SUBSTITUTED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2004-08-04 EP disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed
WO-2003040147-A1 AZABICYCLIC-SUBSTITUTED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE__________________________________________________________________________________________________________________________ PHARMACIA & UPJOHN COMPANY (US) 2003-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 SMN1; SMN2 1751/4885HPGD 706/4885CHRNA7 1097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.